Again, a subgroup analysis of the pneumonitis cases revealed that more patients (59.5%) of PD-1 inhibitors had Grade 3 or higher pneumonitis than PD-L1 inhibitors (43.1%). The gene discussed is PDCD1; the disease is pneumonitis.